In the spring of 2005, families affected by progeria welcomed the news from two studies that uncovered new information about this rare, devastating condition that causes premature aging in children.

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1’s effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir ...

The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, ...

Using new technology, researchers from Texas found that they could reverse many markers of aging in cells from children with progeria, a rare genetic disease that causes rapid aging and early death.

The MarketWatch News Department was not involved in the creation of this content. Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its ...

MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases ...

Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products The agreement will allow ...

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging There are an estimated 400-500 known cases worldwide, including ...